Αρχική World News EMA Recommends Extension of Therapeutic Indications for Ponatinib World News EMA Recommends Extension of Therapeutic Indications for Ponatinib Από Ogkologos - 27 Φεβρουαρίου, 2026 425 0 Facebook Twitter Google+ Pinterest WhatsApp Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR How Adolescent and Young Adult Cancer Survivors Can Cope With the... 17 Νοεμβρίου, 2022 Male Patients with Cancer at Higher Risk of Severe Disease Course... 26 Αυγούστου, 2020 EMA Recommends Granting a Marketing Authorisation for Vimseltinib 5 Σεπτεμβρίου, 2025 Cancer in My Community: Improving Access to Palliative Care in Indonesia 13 Ιανουαρίου, 2022 Φόρτωση περισσοτέρων HOT NEWS Can Acupuncture Help Cancer Survivors with Chronic Pain? Does Too Much Fructose Help Colorectal Cancers Grow? Limited Effect of Endocrine Therapy on Distant Metastasis-Free Interval in Patients... FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy